Table 1.

Patient Characteristics before and after Surgery (n = 119)

Characteristics	No.(%)	Characteristics	No.(%)
Clinical stage		Grade
II B	32 (26.9%)	I	1 (0.8%)
III A	56 (47.1%)	II	67 (56.3%)
III B	22 (18.5%)	III	15 (12.6%)
III C	9 (7.5%)	Not graded	36 (30.3%)
Pre-cALN		Post-cALN
negative	36 (30.3%)	negative	81 (68.1%)
positive	83 (69.7%)	positive	38 (31.9%)
Pre-ER		Post-ER※
negative	58 (48.7%)	negative	82 (75.2%)
positive	61 (51.3%)	positive	27 (24.8%)
Pre-PR		Post-PR※
negative	60 (50.4%)	negative	84 (77.1%)
positive	59 (49.6%)	positive	25 (22.9%)
Pre-HER-2		Post-HER-2※
0-2+	86 (72.3%)	0-2+	79 (72.5%)
3+	33 (27.7%)	3+	30 (27.5%)
Pre-Ki67		Post-Ki67※
≤ 20%	74 (62.2%)	≤ 20%	93 (85.3%)
>20%	45 (37.8%)	>20%	16 (14.7%)
Pathology		Pathological tumor size
IDC	92 (77.3%)	≤ 2 cm	28 (23.5%)
ILC	4 (3.4%)	> 2 cm	59 (49.6%)
other	23 (19.3%)	unmeasured	32 (26.9%)
Clinical response		pALN
CR	27 (22.7%)	N 0	39 (32.8%)
PR	78 (65.6%)	N 1-3	24 (20.2%)
SD	13 (10.9%)	N 4-9	35 (29.4%)
PD	1 (0.8%)	N >9	21 (17.6%)
Pathological response in tumor site
T-A	22 (18.5%)
T-B	75 (63.0%)
T-C	22 (18.5%)

Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

※109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.